The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
One expires this year and it looks like the balance expire in 2 years time
https://www.drugpatentwatch.com/p/tradename/LYNPARZA
This is interesting as it gives an insight to the threat of patent expiry as well as commenting on Lynparza
https://pharmaphorum.com/news/az-says-recovery-to-continue-to-despite-patent-expiry-and-brexit-headwinds/
Tip of the iceberg - as hinted at there are mountains of combination patents that will help protect this franchise
The real threat is not just generics but others in the pipeline
Yeah but Mulder why did you register on this BB with two accounts?
It’s easy if AZ does not need patent protection to 2040 then there will be one or two other pharmas wanting to share the $10bn pa market
0.8p sell, still heading lower, FFS do something!
Pushing down on really low volumes.... hopefully the reverse is the same and it will go up on relatively low volumes.. Its just so under everyone's radar at the moment. They really need to work on their PR machine...
I dont have lvl2 visibility of trades but I can only see one sell at this level for less than £240. Still not a happy to see it reflected on bid. Could we be heading lower still?
Mars, if if we have an improved version of Lynparza I hope they dont do an underpriced sweetheart deal with AZ, but see what Merck & others might want to bid. Given the NXP001 licensing disaster, I am a little worried about our negotiating skillset.
Very low volume however it's still frustrating to see, will keep being patient, these are after all blockbuster drugs.
Large investors must be waiting for something to happen before taking the plunge, clarification over CEO maybe?
JH and DG have watched their shares go from around £5m down to around £300k, still they don't sell, they must have faith in the strategy so taking comfort from that, I just thought we'd be on our way by now
Filter, look like someone wants whole this for very cheap. Knowing our bod, can’t rule that out. They are all together here.
Hi Taz i beginning to think you are correct due to the time taken to get any news out to us share holders. Is there a "complete package" being worked on?. Question is if this is the case how cheap is "very cheap"
Jiving yes past performance not ideal however NXP001 was not a blockbuster and development was for a previously untried area. I should imagine independent valuations will be sought and ignored, the difficulty has become with the enormity of the recent approvals. Current sales are $2.7bn with estimates of $9.7bn by 2028, so value is a challenge, this was originally $1bn blockbuster when NFX started. There is no doubt there is significant value to protect market share, I don’t envy their task, but there are industry specialists who value these assets wish one would just state what they think the drug is worth.
Cheap is a subjective term, depends on percentage of holders they can convince for any TO offer. It's a risk at these levels that the outcome could be below 10p I dont see most accepting ipo price. But personally I dont see TO as realistic possibility yet, like others have said JH and DG still hold, I don't expect them to roll over and accept a cheap offer for their years of work.
Between Lanstead, CPI, JH & DG I guess a cheap takeover is off the table you'd hope
Ironically you'll pay more to buy right now than the first two buys this morning.
Don't believe cpi look at the price. They appear to sell on a regular basis immaterial of price. After all it's only tax payers money, and we all know how civil servants like to peas that up against a wall.
Chab, CPI's sells have all been around the 1.5p region or above. (Mid Feb 22, mid Nov 21)
More daily drops, NFX continues to be one of the most outstanding shares for wealth destruction, excellent option for those out there looking to lose money
How much have you lost blood?
I'm in both camps, I'm excited for the potential to come (eventually) but can't deny the previous mismanagement and wealth destruction for many shareholders
Not lost anything yet as haven't sold the holding I have, but I'm having a fantastic time watching the value of this investment dwindle away to probably nothing, fantastic
Older confirmed NFX had commenced discussions with AZ after the patent submission in November, no other marketing, so is there some intent, so how long to then notify the market or can AZ take as much time as they want
Never seen anything confirming discussions with AZ before Mars, the company has been clear they are waiting for patent grant first.